5 EASY FACTS ABOUT ABBV-744 COMBINATION THERAPY WITH CHEMOTHERAPY DESCRIBED

In Segment A, participants will obtain distinct doses and schedules of oral ABBV-744 tablet to detect Harmless dosing routine. Further participants will be enrolled within the recognized monotherapy dosign program. In Segment B, contributors will get oral ruxolitinib and ABBV-744 will likely be presented as "incorporate-on" therapy. In Phase C, con